Literature DB >> 19579805

Comparative potential of modified indigenous, indigenous and commercial ELISA kits for diagnosis of Mycobacterium avium subspecies paratuberculosis in goat and sheep.

A V Singh1, S V Singh, J S Sohal, P K Singh.   

Abstract

In the present study, modified indigenous ELISA kit (kit 1) was compared with indigenous ELISA kit (kit 2) and commercial ELISA kit (kit 3) for its sensitivity and specificity with respect to faecal culture for diagnosis of Johne's disease in goats and sheep under natural conditions. Of the 64 positive animals, serum of 42.1, 48.4 and 18.7% animals yielded positive infection in kit 1, 2 and 3, respectively. Specificity of kit 1 (95.1%) was maximum followed by kit 3 (93.7%) and kit 2 (83.4%). Kit 1 showed superior diagnostic potential than the other two kits. Kit 1 may be used as single screening test regimen for diagnosis of MAP infection in the population of goats and sheep in India.

Entities:  

Mesh:

Year:  2009        PMID: 19579805

Source DB:  PubMed          Journal:  Indian J Exp Biol        ISSN: 0019-5189            Impact factor:   0.818


  3 in total

1.  Evaluation of "Indigenous Absorbed ELISA Kit" for the Estimation of Seroprevalence of Mycobacterium avium Subspecies paratuberculosis Antibodies in Human Beings in North India.

Authors:  A V Singh; S V Singh; D K Verma; R Yadav; P K Singh; J S Sohal
Journal:  ISRN Vet Sci       Date:  2011-05-23

Review 2.  Current status of Mycobacterium avium subspecies paratuberculosis infection in animals & humans in India: What needs to be done?

Authors:  Ajay Vir Singh; Devendra Singh Chauhan; Shoor Vir Singh; Vijay Kumar; Abhinendra Singh; Anjali Yadav; Virendra Singh Yadav
Journal:  Indian J Med Res       Date:  2016-11       Impact factor: 2.375

3.  Novel recombinant Mce-truncated protein based ELISA for the diagnosis of Mycobacterium avium subsp. paratuberculosis infection in domestic livestock.

Authors:  Zahra Hemati; Masoud Haghkhah; Abdollah Derakhshandeh; Kundan Kumar Chaubey; Shoor Vir Singh
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.